Related Experiment Videos
Neoadjuvant chemotherapy for invasive bladder cancer
1Urologic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Seminars in Surgical Oncology
|January 1, 1989
Summary
Neoadjuvant chemotherapy shows promise for locally advanced bladder cancer by inducing tumor regression. However, challenges like tumor heterogeneity and patient selection raise questions about its overall effectiveness.
Area of Science:
- Uro-oncology
- Medical oncology
- Clinical research
Background:
- Neoadjuvant chemotherapy is increasingly used for locally advanced bladder cancer.
- Rationale includes responses in metastatic disease and high relapse rates after local treatment.
- Potential for predictive biomarkers and bladder preservation exists.
Purpose of the Study:
- To evaluate the efficacy and challenges of neoadjuvant chemotherapy in locally advanced bladder cancer.
- To explore the impact of tumor heterogeneity and patient selection on treatment outcomes.
Main Methods:
- Review of clinical data and treatment responses.
- Analysis of factors influencing neoadjuvant chemotherapy effectiveness.
- Assessment of tumor regression and systemic relapse rates.
Main Results:
- Neoadjuvant chemotherapy can achieve significant clinical and pathologic tumor regression.
- Observed responses in metastatic bladder cancer support its use.
- High systemic relapse rates after local control highlight treatment limitations.
Conclusions:
- While neoadjuvant chemotherapy offers benefits, its overall efficacy is questioned.
- Bladder tumor heterogeneity, patient selection, and evaluation methods present significant challenges.
- Further research is needed to optimize neoadjuvant therapy for bladder cancer.